Our results indicated that high levels of AHNAK2 expression were significantly associated with poor survival rates in GBM patients from the CGGA and TCGA datasets, when compared to those with low AHNAK2 expression (S2 Fig in S1 File). This evidence concerns the gene AHNAK2 and glioblastoma.